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Coagulation factor XIII (FXIII) is a stepchild among
clotting factors. As opposed to all other zymogenic clot-
ting factors, it is not the precursor of a proteolytic
enzyme but of a transglutaminase. It is of tetrameric
structure consisting of two types of subunits (FXIII-
A2B2). In the final step of the coagulation cascade the A
subunit (FXIII-A) is transformed into an active enzyme
by the concerted action of thrombin and Ca2+. Thrombin
cleaves off an activation peptide (AP-FXIII) of 37 amino
acids from the N-terminal end of FXIII-A. Subsequently,
in the presence of Ca2+, the protective/inhibitory B sub-
units (FXIII-B) dissociate from the cleaved A´ subunits,
which then assume an active configuration (FXIII-A*).
Activated FXIII is a transglutaminase, the main function
of which is the cross-linking of fibrin a and fibrin c chains
and the attachment of a2-plasmin inhibitor to fibrin
through e(c-glutamyl) lysyl isopeptide bonds. This way
FXIII is involved in mechanically strengthening the fibrin
clot and protecting it from fibrinolytic degradation. A
dimer of FXIII-A lacking the B subunits is also expressed
in several cell types, including platelets, monocytes,
macrophages, osteoblasts, chondrocytes, and preadipo-
cytes in which it exerts diverse functions. The intracellular
activation of FXIII-A2 does not need limited proteolytic
involvement. The elevation of the Ca2+ level in the cyto-
plasm is sufficient to convert FXIII-A2 to an active con-
figuration (FXIII-A°). (For comprehensive reviews see
references [1–5].)
X-ray crystallography revealed the atomic resolution
structure of FXIII-A2 and demonstrated that the FXIII-
A monomer contains four domains (b-sandwich, cat-
alytic core, b-barrel 1, and b-barrel 2) and AP-FXIII
[6,7]. The crystallographic structure of FXIII-B is not
available. This protein is of mosaic structure, it consists
of 10 short tandem repeats (sushi domains) each con-
taining about 60 amino acids and held together by a
pair of disulfide bonds [8]. Our knowledge on the struc-
ture of FXIII and on structural changes during FXIII
activation was enriched by important studies using elec-
tron microscopy, size exclusion chromatography, analyti-
cal ultracentrifugation, H-D exchange, mass
spectrometry, and molecular modeling [2,9–13]. The use
of high-resolution single-molecule atomic force micro-
scopy (AFM) in the study of Protopopova et al., pub-
lished in this issue of JTH, provides a new dimension to
this extensive line of research [14]. This technique visual-
izes the surface topology/contour of the molecule rather
than the protein backbone, and this way an additional
aspect of structural information is revealed. The authors
investigated the morphology of the tetrameric FXIII-
A2B2 complex and the individual subunits. The struc-
tural changes induced by thrombin and Ca2+ were also
demonstrated.
The structure of FXIII and its subunits
Based on early electronmicroscopic studies it was sug-
gested that two FXIII-B subunits are wrapped around the
FXIII-A dimers [9]. This hypothesis was supported by the
finding that the presence of FXIII-B protects the A sub-
units from proteolytic inactivation [10,14]. The AFM pic-
tures produced by Protopopova et al. provide a
remarkably novel insight into the structure of FXIII-
A2B2. In the published study it is clearly demonstrated
that within the tetrameric structure, FXIII-A2 is repre-
sented by a globular part of moderate ovality. In the
majority of cases two strands corresponding to mono-
meric FXIII-B extend from the globular part; however,
there were also minor structural variants with only one or
no thin flexible extensions. This structural diversity very
likely reflects the equilibrium between association and dis-
sociation of FXIII-B subunits from the A2 dimer.
According to the AFM data, 26% of the B subunits dis-
sociate from the globular core, while 74% are connected
to the globules, which is in excellent agreement with the
values calculated from the actual FXIII concentration
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(~6.3 nM) and the Kd (4.17 9 1010 M) [15]. Earlier
reports suggested that the first two N-terminal sushi
domains of FXIII-B are involved in the association to
FXIII-A2 [10,15], which was confirmed by the AFM pic-
tures. As expected, the individual FXIII-A monomers in
the complex are not resolved by AFM. The location of
FXIII-B in the complex is somewhat surprising. As dis-
cussed later, the individual free FXIII-B molecules form
dimers, and it is not clear how the FXIII-B dimer falls
apart into monomers to be able to combine with an indi-
vidual FXIII-A molecule. The binding site for FXIII-B
on FXIII-A also needs to be specified to explain how the
two FXIII-B monomers enter the compact/closed struc-
ture of FXIII-A2. Such investigations might be relevant
for FXIII-A-deficient patients receiving recombinant
FXIII-A2 for prophylaxis: in these patients the binding of
recombinant FXIII-A2 to the patient’s FXIII-B is essen-
tial for the formation of heterotetramers, which in con-
trast to uncomplexed FXIII-A2 have a long half-life in
the plasma.
Earlier reports concerning the dimeric or monomeric
state of free FXIII-B were controversial. Sedimentation
analysis and low-resolution electronmicroscopic images
suggested free FXIII-B to be a flexible and kinked mono-
meric structure [9], while gel filtration experiments sug-
gested the protein to be a dimeric structure [10,16]. In the
present study the dimeric nature of free FXIII-B was
clearly confirmed. It has been shown that the measured
length of FXIII-B dimer corresponded to a previously sug-
gested model, in which the two FXIII-B subunits have an
antiparallel orientation, which is ensured by the interaction
of sushi domains 4 and 9 [10]. Accepting this model, further
experiments are needed to explain the mechanism of com-
plex formation considering that the two N-terminal sushi
domains are positioned at the opposite ends of the dimeric
strand. One possibility is that the two opposite ends of
FXIII-B2 bind to FXIII-A molecules present in distinct
FXIII-A dimers. The other possibility is that the binding of
a FXIII-B subunit to FXIII-A2 induces the dissociation of
the FXIII-B2 and the released FXIII-B monomer becomes
available for combining with FXIII-A2. Obviously such
speculations and others call for experimental support.
Structural changes upon FXIII activation
Earlier reports suggested that after activation of FXIII-
A2B2 and FXIII-A2 by thrombin and Ca
2+ the two active
subunits stick together (FXIII-A2*) and express transglu-
taminase activity. Most recently this paradigm has been
challenged. The dissociation of FXIII-A2 into FXIII-A*
monomers upon both proteolytic and non-proteolytic
activation was demonstrated by analytical ultracentrifuga-
tion, and FXIII-A* also remained monomeric upon bind-
ing of substrate analogs [11]. Protopopova et al. provided
direct evidence on the monomeric form of FXIII-A* by
AFM [14]. Using volume calculations the FXIII-A2 dimer
was found to be 2.3-fold larger than FXIII-A*. Molecular
modeling also supported a monomeric form for FXIII-A*
[13,17]. The monomeric structure of all other active trans-
glutaminases is in line with these findings [2,18]. Based on
the results of Protopopova et al. and on earlier findings a
schematic representation of FXIII activation is proposed
in Fig. 1. The transformation of FXIII-A does not induce
drastic conformational changes within a particular
domain. However, the changes in the position of individ-
ual domains indicate considerable structural transitions,
usually termed as transition from closed/compact to
open/extended structure (reviewed in references [2,19]).
The resolution of single-molecule AFM does not seem
sufficient to capture such a difference.
The introduction of high-resolution single-molecule
AFM opens new perspectives in FXIII structural
research. It helps in evaluating controversial issues and
might confirm or contradict existing paradigms. New
findings by this technique contribute to our better under-
standing of the structural-functional relationship of this
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FIGURE 1. Schematic representation of proteolytic FXIII activation. The A subunit of (FXIII-A) is depicted in blue. Elongated strands con-
sisting of gray pearls represent the FXIII B subunit (FXIII-B) consisting of sushi domains. Activation peptides (AP-FXIII) are shown as red
loops. FXIII-A´, FXIII-A cleaved by thrombin; FXIII-A*, FXIII activated by thrombin; Ca2+ (active transglutaminase).
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unique coagulation factor and its role in the hemostatic
mechanism.
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